Effect of Potassium Canrenoate, an Anti-aldosterone Agent, on Incidence of Ascites and Variceal Progression in Cirrhosis  Luigi Bolondi, Fabio Piscaglia, Angelo Gatta, Francesco Salerno, Mauro Bernardi, Antonio Ascione, Oscar Ferraù, David Sacerdoti, Stefania Visentin, Franco Trevisani, Roberto Mazzanti, Gabriele Donati, Umberto Arena, Paolo Gentilini  Clinical Gastroenterology and Hepatology  Volume 4, Issue 11, Pages 1395-1402 (November 2006) DOI: 10.1016/j.cgh.2006.06.005 Copyright © 2006 AGA Institute Terms and Conditions

Figure 1 Patient flow after randomization. hcc, hepatocellular carcinoma; Dev., development of. Clinical Gastroenterology and Hepatology 2006 4, 1395-1402DOI: (10.1016/j.cgh.2006.06.005) Copyright © 2006 AGA Institute Terms and Conditions

Figure 2 Probability of remaining free from any end point (onset of ascites, development of esophageal varices, or progression of F1 varices) in patients receiving placebo (, group A, n = 51) or Kcanrenoate (•, group B, n = 47). The difference between the groups is statistically significant (P = .048). Clinical Gastroenterology and Hepatology 2006 4, 1395-1402DOI: (10.1016/j.cgh.2006.06.005) Copyright © 2006 AGA Institute Terms and Conditions